CSCI 株価分析 — Cosciens Biopharma Inc. (Healthcare >> Biotechnology)
CSCI に関するよくある質問
CSCIのROE(自己資本利益率)は?
Cosciens Biopharma Inc.のROEは-265.34%です。
CSCIの配当利回りは?
Cosciens Biopharma Inc.の配当利回りは0.00%です。
CSCIの品質スコア(Quality Score)は?
当社のAIはCSCIの総合財務品質を100点中23点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
CSCIは今が買い時ですか?
当社AIのタイミングスコアは100点中5点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
CSCIはどのセクターに属しますか?
Cosciens Biopharma Inc.はHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
CSCI AI Analysis Summary
Our AI summary for CSCI: Cosciens Biopharma Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -265.34%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 5/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 7.10
Price
-0.65
(-8.39%)
Day Change
|
|
|---|
CSCI, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.10 |
| PBV / Sector |
1.22 / 5.21
GOOD
|
| Earning Per Share | -15.47 |
| PE / Sector |
N/A / 21.00
|
| PEG or PE/Growth / Sector |
N/A / 1.11
|
| Average 1M Daily Value |
7672.917000000000
|
| Average 1W Daily Value |
0.01 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-07 08:11:30 |
| Symbol | CSCI |
| Name | COSCIENS BIOPHARMA INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 3.18 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 8.64 / 9,672.56 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 222 Bay Street, Toronto, ON, Canada, M5K 1E7
Phone: -
Website: https://www.cosciensbio.com
Sector: Healthcare >> Biotechnology
Description: COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Colombia, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a chewable for cholesterol reduction; beta glucan from yeast, a nutraceutical-capsule used as an immune booster; and avenanthramides, a nutraceutical-chewable formulation used to reduce inflammation for the healthcare and cosmetic industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as for endocrinology and oncology indications. The company sells its products through its distribution network. It has license agreements with Pharmanovia, MegaPharm Ltd., ER Kim Pharmaceuticals Bulgaria Eood, and NK MEDITECH Ltd, as well as Agriculture Canada and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google